<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03816397</url>
  </required_header>
  <id_info>
    <org_study_id>17-23987</org_study_id>
    <secondary_id>UG1EY029658</secondary_id>
    <nct_id>NCT03816397</nct_id>
  </id_info>
  <brief_title>Adalimumab in JIA-associated Uveitis Stopping Trial</brief_title>
  <acronym>ADJUST</acronym>
  <official_title>Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nisha Acharya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alder Hey Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheffield Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a stratified, block-randomized, double-masked, controlled trial to
      determine the feasibility of discontinuing adalimumab treatment in patients with quiescent
      uveitis associated with juvenile idiopathic arthritis (JIA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From baseline until 12 months post-randomization</time_frame>
    <description>Time to treatment failure until 12 months post-randomization. Treatment failure is defined by recurrence of ocular inflammation in at least one eye as follows:
3+ anterior chamber (AC) for a single visit
•&gt;0.5+ anterior chamber (AC) cell for ≥28 days
2-step increase in AC cell observed at two separate visits ≥7 days apart
0.5+ vitreous haze, active retinal or choroidal inflammation, or macular edema observed at two separate visits ≥7 days apart. Treatment failure can also be declared by recurrence of joint inflammation that is persistent and severe enough to necessitate unmasking to manage the arthritis recurrence.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Uveitis</condition>
  <condition>JIA</condition>
  <arm_group>
    <arm_group_label>Continue adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop adalimumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8mL and 40mg/0.8mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.</description>
    <arm_group_label>Continue adalimumab</arm_group_label>
    <other_name>HUMIRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The placebo is designed to match the characteristics of the citrate-free adalimumab during injection.</description>
    <arm_group_label>Stop adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (must meet all of the following to qualify):

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study period

          -  ≥ 2 years of age

          -  History of JIA diagnosed prior to 16 years of age (patient may be older than 16 at
             time of enrollment)

          -  ≥12 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell,
             ≤0.5+ vitreous haze, no active retinal/choroidal lesions in either eye, no macular
             edema)

          -  ≥ 12 consecutive months of controlled arthritis verified by a pediatric rheumatologist

          -  ≥12 consecutive months of treatment with adalimumab or a biosimilar of adalimumab

          -  ≥180 days on a stable dose of adalimumab or a biosimilar; must be biweekly dose of
             either 20mg (if&lt;30kg) or 40mg (if ≥30kg)

          -  If on a biosimilar of adalimumab, ≥90 days on the biosimilar

          -  If on concomitant methotrexate, dose must be ≤25mg weekly and stable for ≥90 days

          -  If on concomitant mycophenolate mofetil, dose must be ≤3g daily and stable for ≥90
             days

          -  If on topical corticosteroids, dose must be ≤2 drops prednisolone acetate 1% or
             equivalent per day and stable for ≥90 days

          -  Willingness to limit consumption of alcohol during the study period

          -  Agreement to avoid live attenuated vaccinations

          -  Agreement to use highly effective contraception for ≥28 days prior to screening and
             throughout study period (for males and females of reproductive age)

          -  A negative tuberculosis (TB) test within the past 12 months or a positive test for TB
             with a history of completed treatment for latent TB

          -  Suitable, in the opinion of the Investigator, to continue treatment with adalimumab or
             placebo per regional labeling

          -  No contraindications to receive adalimumab as per the local Summary of Product
             Characteristics (SmPC)

        Exclusion Criteria (any one of these excludes the patient):

          -  Intraocular surgery in the past 90 days or planned surgery in the next 180 days

          -  Severe cataract or opacity preventing view to the posterior pole in both eyes

          -  Chronic hypotony (&lt;5mmHg for ≥90 days) in either eye

          -  Treatment with oral corticosteroids or intraocular corticosteroid injection within the
             last 12 months

          -  Current use of NSAID eye drops

          -  Acute anterior uveitis characterized by redness and symptoms, including but not
             limited to floaters, pain, and light sensitivity

          -  Pregnancy or lactation (a pregnancy test will be conducted at baseline and all
             follow-up visits for females of reproductive age)

          -  Prior safety or tolerability issues with adalimumab

          -  History of cancer, active tuberculosis, or hepatitis B

          -  Other medical condition expected to dictate treatment course during the study

          -  Any of the following abnormal lab values within 28 days prior to enrollment: leukocyte
             count &lt;2500, platelet count ≤75000, hemoglobin&lt;9.0, AST or ALT ≥ 2 times the upper
             limit of normal range, creatinine ≥1.5

        There are no sex, race, or ethnicity restrictions for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Acharya, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisha Acharya, MD MS</last_name>
    <phone>415-476-8131</phone>
    <email>nisha.acharya@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisha Acharya, MD MS</last_name>
    </contact>
    <investigator>
      <last_name>Nisha Acharya, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Gonzales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thuy Doan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Thorne, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jennifer Thorne, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Stahl, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erin Stahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Miraldi Utz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adam Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelia Angeles-Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginia Miraldi Utz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Davidson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefanie Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Lerman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Vitale, MD</last_name>
    </contact>
    <investigator>
      <last_name>Albert Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aimee Hersh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Cabrera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michelle Cabrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Herlihy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kabita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robyn Troutbeck</last_name>
    </contact>
    <investigator>
      <last_name>Robyn Troutbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lyndell Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Munro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A V Ramanan</last_name>
    </contact>
    <investigator>
      <last_name>A V Ramanan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Dick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kate Armon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brinda Muthusamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 5AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Gonzalez-Martin</last_name>
    </contact>
    <investigator>
      <last_name>Jose Gonzalez-Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gavin Clearly</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Beresford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ameenat Solebo</last_name>
    </contact>
    <investigator>
      <last_name>Ameenat Solebo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clive Edelsten</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Lacassagne</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucy Wedderburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great North Children's Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Clarke</last_name>
    </contact>
    <investigator>
      <last_name>Michael Clarke</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharmila Jandial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 6TZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kate Armon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Narman Puvanachandra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessy Choi</last_name>
    </contact>
    <investigator>
      <last_name>Jessy Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Hawley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina May</last_name>
    </contact>
    <investigator>
      <last_name>Kristina May</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Leahy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.</citation>
    <PMID>27602665</PMID>
  </reference>
  <reference>
    <citation>Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Erratum in: Lancet. 2016 Sep 17;388(10050):1160.</citation>
    <PMID>27542302</PMID>
  </reference>
  <reference>
    <citation>Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, Hickey H, Hughes D, Jones A, Woo P, Edelsten C, Beresford MW; SYCAMORE Trial Management Group. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014 Jan 9;15:14. doi: 10.1186/1745-6215-15-14.</citation>
    <PMID>24405833</PMID>
  </reference>
  <reference>
    <citation>Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006 Oct;149(4):572-5.</citation>
    <PMID>17011337</PMID>
  </reference>
  <reference>
    <citation>Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015 May;67(5):658-66. doi: 10.1002/acr.22477.</citation>
    <PMID>25220674</PMID>
  </reference>
  <reference>
    <citation>Baszis K, Garbutt J, Toib D, Mao J, King A, White A, French A. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011 Oct;63(10):3163-8. doi: 10.1002/art.30502.</citation>
    <PMID>21702011</PMID>
  </reference>
  <reference>
    <citation>Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222. Epub 2013 Jul 22.</citation>
    <PMID>23876234</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Nisha Acharya</investigator_full_name>
    <investigator_title>Director, Uveitis and Ocular Inflammatory Disease Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

